Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: Finlabo SIM Spa
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bayer AG Gets European Approval of VEGF Trap-Eye to Treat AMD-DJ


Tuesday, 27 Nov 2012 02:16am EST 

Dow Jones reported that Bayer AG has received European Commission approval for EYLEA, also known as VEGF Trap-Eye, to treat wet age-related macular degeneration. The treatment is already approved in the United States, Australia and Japan. The Company also said that it will launch EYLEA in Japan soon. 

Company Quote

144.94
7.77 +5.66%
18 Sep 2014